CANF (Can Fite Biopharma) Shiller PE Ratio: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CANF Can Fite Biopharma Ltd CANF
60 GF Score
Price $3.35
GF Value $5.79
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Can Fite Biopharma  (AMEX:CANF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Can Fite Biopharma Shiller PE Ratio Related Terms


Can Fite Biopharma Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Can Fite Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Can Fite Biopharma Shiller PE Ratio Chart

Can Fite Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Can Fite Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CANF vs VRTX, REGN, RVMD: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Can Fite Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biopharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biopharma's Shiller PE Ratio falls into.


CANF
60GF Score
Can Fite Biopharma Ltd CANF
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Can Fite Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Can Fite Biopharma's E10 for the fiscal year that ended in Dec25 is calculated as:

For example, Can Fite Biopharma's adjusted earnings per share data for the fiscal year that ended in Dec25 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec25 (Change)*Current CPI (Dec25)
=-10.746/324.0540*324.0540
=-10.746

Current CPI (Dec25) = 324.0540.

Can Fite Biopharma Annual Data

Earnings per Share (Diluted) CPI Adj_EPS
201612 -1,800.000 241.432 -2,415.990
201712 -1,140.000 246.524 -1,498.522
201812 -1,020.000 251.233 -1,315.652
201912 -840.000 256.974 -1,059.272
202012 -240.000 260.474 -298.582
202112 -180.000 278.802 -209.216
202212 -60.000 296.797 -65.510
202312 -32.256 306.746 -34.076
202412 -19.548 315.605 -20.071
202512 -10.746 324.054 -10.746

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Can Fite Biopharma (CANF) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of $3.35 is trading 42.1% below its estimated GF Value™ of $5.79. GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.

Key valuation signals for CANF:

  • Shiller PE Ratio:
  • GF Value™: $5.79 vs. price of $3.35 (42.1% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Can Fite Biopharma Business Description

Other Exchanges CANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score

Get the complete analysis for CANF

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.35
Price
$5.79
GF Value